Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.68 |
| ▸ | MEN1 | O00255 | 10/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325897 | 0.82 | KMT2A (0.69) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL1421163 | 0.81 | KMT2A (1.00) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL948141 | 0.79 | MEN1 (0.47) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL948142 | 0.79 | MEN1 (0.47) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL11118610 | 0.79 | KMT2A (0.72) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL8206174 | 0.78 | KMT2A (1.00) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL11118190 | 0.77 | KMT2A (0.68) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL181796 | 0.76 | KMT2A (0.69) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL3041005 | 0.75 | KMT2A (1.00) | KMT2AMEN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL12726822 | 0.75 | KMT2A (0.69) | KMT2AMEN1L3MBTL1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058295-B2 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2279029-A2 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | The Regents of the University of California (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100130571-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130571-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-27 | — | — | US | disclosed |
| US-7638543-B2 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638543-B2 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-29 | — | — | US | disclosed |
| WO-2009120803-A2 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20080064666-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064666-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | US | disclosed |
| US-7235573-B2 | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235573-B2 | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1549321-A4 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1549321-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | disclosed |
| WO-2004028480-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130571-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | CFTR, TMEM205, TMEM33 | KMT2A 4563/4885MEN1 4413/4885L3MBTL1 3282/4885 |
| US-20080064666-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | CFTR, TMEM205, TMEM33 | KMT2A 4563/4885MEN1 4413/4885L3MBTL1 3282/4885 |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | CFTR, TMEM205, TMEM33 | KMT2A 4563/4885MEN1 4413/4885L3MBTL1 3282/4885 |
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, PKD1, PKD2 | KMT2A 4437/4885MEN1 2136/4885L3MBTL1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.